Back to discover
Disease
Liposarcoma
Late-stage therapeutic developmentEmerging research
1
Publications
18
Clinical trials
12
Associated genes
2
Related proteins
2007
Latest publication
Current focus
Rna-binding ews biologyRna-binding fus biologyTherapeutic development
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Approval: Eribulin Baxter (EMA)
Regulatory2024-06-27EMA
Regulatory2024-02-09EMA
Regulatory2011-03-17EMA
Adipose-derived stem cells for regenerative medicine.
Research2007-05-01Circulation research
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 3 clinical trials expected to report results, the earliest in Q3 2027.
Upcoming Milestones
- Q3 2027Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
- Q4 2027Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma
- Q2 2035A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20352026-08-27
Major trial resultsHigh impact
Results posted2026-03-02
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-08-27A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated SarcomasResults expected Q2 2035
- 2026-06-08Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated LiposarcomaResults expected Q3 2027
- 2026-03-05Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated LiposarcomaResults expected Q4 2027
Recently completed
- 2026-06-01A Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated LiposarcomaPrimary completion
- 2025-12-01SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaPrimary completion
Other updates
- 2025-10-01Time to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial SarcomaWithdrawn
- 2025-09-28A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated LiposarcomaTerminated
Activity timeline8
- 2026-08-27ClinicalA Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated SarcomasResults expected Q2 2035
- 2026-06-08ClinicalPhase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated LiposarcomaResults expected Q3 2027
- 2026-06-01ClinicalA Phase II Study of CDK4/6 Inhibition (Palbociclib) Combined With PD-1 Blockade (INCMGA00012) in Patients With Advanced Well-differentiated Dedifferentiated LiposarcomaPrimary completion
- 2026-03-05ClinicalPhase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated LiposarcomaResults expected Q4 2027
- 2026-03-02ClinicalBrightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of Brigimadlin (BI 907828) Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated LiposarcomaResults posted
- 2025-12-01ClinicalSARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated LiposarcomaPrimary completion
- 2025-10-01ClinicalTime to Secondary Resistance to Trabectedin After Interruption Versus Continuation in Responding Patients With Liposarcoma, Leiomyosarcoma and Synovial SarcomaWithdrawn
- 2025-09-28ClinicalA Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated LiposarcomaTerminated
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approved & established therapies
Trabectedinapproved
Approval — Trabectedin Accord is indicated for the treatment of adult patients with advanced soft ti… (2025)
Eribulin mesylateapproved
Approval — Eribulin Baxter is indicated for the treatment of adult patients with locally advanced or… (2024)
Eribulinapproved
Approval — Halaven monotherapy is indicated for the treatment of patients with locally advanced or m… (2011)
Clinical trials
The current development programme across all trial phases.
Clinical programme
18
6
8
6
Late-stage studies
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
First approvals
2025emaApproval — Trabectedin· Trabectedin Accord is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Trabectedin Accord in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. source ↗
2024emaApproval — Eribulin mesylate· Eribulin Baxter is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Eribulin Baxter is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease source ↗
2024emaApproval — Eribulin mesylate· Mevlyq is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. Mevlyq is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. source ↗
2011emaApproval — Eribulin· Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1). source ↗
2007emaApproval — Trabectedin· Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Most influential
Recent publications
Major themes2
- Cell Differentiation1
- Tissue Engineering1
Leading journals1
- Circulation research1
Leading researchers3
- Bunnell BA1
- Gimble JM1
- Katz AJ1
Affiliations (unnormalised)1
- Stem Cell Biology Laboratory and Clinical Nutrition Research Unit1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.